PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
AetnaCommercial · Coverage · Pharmacy · Ophthalmology, Vascular SurgeryMedium impact

Novel Injection Methods (CPB 0777, reviewed 2025-12-02)

Effective date
Not stated in the notice
Identified
Aug 17, 2026
Replaced. This version was replaced by Novel Injection Methods (CPB 0777, reviewed 2026-10-27) (published Oct 27, 2026).

Summary

Aetna considers suprachoroidal injection of triamcinolone acetonide injectable suspension (Xipere) medically necessary for macular edema associated with uveitis when the criteria in CPB 1000 are met. Aetna considers suprachoroidal injection of all other pharmacologic agents experimental, investigational or unproven for all indications, and considers sub-retinal injection of recombinant tissue plasminogen activator (rtPA) for the treatment of sub-macular hemorrhage medically necessary. The Mercator Bullfrog micro-infusion device is considered experimental, investigational or unproven for direct adventitial delivery of diagnostic or therapeutic agents via blood vessel walls.

Get alerts when payers change rules like this one

We check Aetna and other payers every day and email you when a change matches your specialty and state.

Get Aetna alertsPolicy Monitoring is free. No card required.

What to do

Action · 4 steps
01Billing team: Bill suprachoroidal injection of Xipere (CPT 67516 with HCPCS J3299, 1 mg) with ICD-10 H35.81 (retinal edema) only for macular edema associated with uveitis when the criteria in CPB 1000 are met.
02Do not schedule or bill suprachoroidal injection of any other pharmacologic agent, because CPT 67516 and CPT 0699T are not covered for the indications listed in the policy and Aetna considers suprachoroidal delivery of all other agents experimental, investigational or unproven for all indications.
03Bill sub-retinal injection of rtPA with CPT 0810T for sub-macular hemorrhage, using the ICD-10 retinal hemorrhage codes H35.60 through H35.63.
04Do not bill HCPCS C9759 for the Mercator Bullfrog micro-infusion device, because it is not covered for direct adventitial delivery and Aetna considers that use experimental, investigational or unproven.

Codes mentioned

67516J3299C9759H35.81

Original notice

Novel Injection Methods (CPB 0777, reviewed 2025-12-02)
aetna.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account